EPS is a Screening Site for new Gene Therapy LUXTURNA™ By Eye Physicians and Surgeons, P.A. on February 06, 2018

                            

American Society of Retina Specialists (ASRS) reports that LUXTURNA™, a one-time gene therapy treatment, has been approved by the FDA.  This is exciting news to retina specialists as they have new hope to offer those with IRD –more specifically a particular Inherited Retinal Disease.  In order to receive this treatment a patient must be tested to see if they have viable retinal cells.  We are happy to report that EPS is a screening site and we are well supplied with test kits.  It is important to note that most of those who have confirmed gene mutation-associated retinal dystrophy will progress to blindness, therefore our Retina Specialists, Dr. Paula Ko and Dr. Carolyn Glazer-Hockstein, are excited to have this new treatment available.  If you need to be tested for this therapy simply call 302-652-3353 and our reception group will be happy to get you scheduled.

ASRS offers the following sources of information about this treatment:

• Foundation Fighting Blindness: http://www.blindness.org/

• Info on gene therapy, genetic testing, living with IRDs: www.ASharedVision.com        

• Information on LUXTURNA™, ocular gene therapy treatment centers, and genetic testing program: www.Luxturna.com

• Information on Spark patient support services: 1-833-SPARK-PS (1-833-772-7577).

Further information can be found in the press release http://ir.sparktx.com/news-releases/news-release-details/fda-approves-spark-therapeutics-luxturnatm-voretigene-neparvovec from Spark Therapeutics, manufacturers of LUXTURNA™.

Related to This

• All Blog Posts
• Blindness
• Gene Therapy
• Fda